ArticleAnalytical and bioanalytical chemistry2026
Dual-tetrahedral DNA-enabled strand displacement amplification biosensor for cell imaging and clinical detection of miR-34a-5p in NAFLD.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The clinical diagnosis of nonalcoholic fatty liver disease (NAFLD) remains challenging due to the invasiveness of liver biopsy and the lack of reliable serum biomarkers, particularly for detecting low-abundance, highly homologous microRNAs such as miR-34a-5p. Here, we constructed a dual-tetrahedral DNA nanostructure biosensor (named DTDN) that couples a target-triggered strand displacement reaction with a catalytic feedback amplification circuit within a rigid tetrahedral scaffold. Unlike conventional molecular beacon or linear probe designs, this spatial architecture accelerates recognition kinetics and suppresses false-positive signals from complex biological matrices, allowing the DTDN probe to discriminate miR-34a-5p from single-base mismatched family members and to achieve a detection limit of 500 fM directly in untreated serum. Importantly, the DTDN accurately quantifies circulating miR-34a-5p levels in NAFLD individuals, which correlate significantly with lipid profiles and transaminase levels. Beyond clinical detection, the same design enables high-contrast live-cell imaging for real-time tracking of miR-34a-5p dynamics in hepatocytes under metabolic stress. By overcoming key barriers-low abundance, sequence homology, matrix interference, and lack of non-invasive spatial readouts-this dual-tetrahedral platform offers a translational route for early NAFLD diagnosis and broader miRNA-based liquid biopsy applications.
Indexed as
Identifiers
42811206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.